jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Thigh mass biopsy - Medium 1-3 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Biopsy of thigh tumor/mass.

₹370₹529

30% OFF

Thigh Mass Biopsy - Medium 1-3 cm: Comprehensive Medical Test Guide

  • Why is it done?
    • Purpose: A thigh mass biopsy is performed to obtain tissue samples from a palpable or imaging-detected mass in the thigh region (1-3 cm in size) for histopathological examination and definitive diagnosis.
    • Primary Indications: To differentiate benign lesions from malignant tumors, establish diagnosis of soft tissue neoplasms, guide treatment planning, and determine prognosis.
    • Timing of Test: Performed when imaging studies (ultrasound, MRI, or CT) reveal an indeterminate mass or when clinical suspicion warrants tissue diagnosis for a persistent thigh lesion lasting more than 2-4 weeks.
    • Common Clinical Scenarios: Evaluation of soft tissue masses suspected of being lipomas, fibromas, liposarcomas, leiomyosarcomas, or other sarcomas.
  • Normal Range
    • Result Interpretation: Biopsy results are reported as histopathological diagnoses rather than numeric values. There is no 'normal' range; results are categorical and descriptive.
    • Benign Findings (Negative for Malignancy): Lipoma, fibroma, myoma, hemangioma, ganglion cyst, or other benign soft tissue lesions; indicates no evidence of malignancy.
    • Malignant Findings (Positive for Malignancy): Liposarcoma, leiomyosarcoma, synovial sarcoma, rhabdomyosarcoma, or other soft tissue sarcomas; indicates presence of malignant cells.
    • Indeterminate/Inconclusive Results: May require repeat biopsy, larger sampling, or additional immunohistochemical studies for definitive classification.
    • Units of Measurement: Histopathological description with grade (for malignancies: Grade 1 Low, Grade 2 Intermediate, Grade 3 High) and staging information.
  • Interpretation
    • Benign Soft Tissue Lesions: Indicates a non-cancerous mass; typically managed conservatively with observation, reassurance, or surgical excision if symptomatic or cosmetically concerning.
    • Low-Grade Sarcomas: Slow-growing malignancy with lower metastatic potential; typically managed with wide surgical excision with negative margins; may or may not require adjuvant therapy depending on size, depth, and histologic subtype.
    • High-Grade Sarcomas: Aggressive malignancy with high metastatic risk; requires wide surgical resection with negative margins, often combined with adjuvant chemotherapy and/or radiation therapy; necessitates staging with CT chest, metastatic survey.
    • Factors Affecting Interpretation: Specimen quality and adequacy, sampling location (superficial vs. deep lesions may affect diagnosis), technical handling, and pathologist expertise in soft tissue neoplasms.
    • Clinical Significance of Grading: Tumor grade predicts behavior, prognosis, and treatment intensity; higher grades indicate greater risk of recurrence and metastasis, requiring more aggressive management.
    • Molecular and Cytogenetic Findings: Some soft tissue sarcomas have characteristic genetic alterations (e.g., Ewing sarcoma with t(11;22)) that aid in diagnosis and may guide targeted therapy options.
  • Associated Organs
    • Primary Anatomical Structures: Soft tissues of the thigh including skeletal muscle, adipose tissue, fascia, blood vessels, and nerves; lesions may originate in subcutaneous or deep compartments.
    • Common Benign Diagnoses: Lipoma (most common), fibroma, myoma, hemangioma, schwannoma, neurofibroma, ganglion cyst, epidermoid cyst; generally do not progress or metastasize.
    • Common Malignant Diagnoses: Liposarcoma (most common adult soft tissue sarcoma of thigh), leiomyosarcoma, synovial sarcoma, fibrosarcoma, rhabdomyosarcoma (more common in children), malignant peripheral nerve sheath tumor (MPNST).
    • Potential Complications from Abnormal Results: Metastatic disease (lungs, bone, liver, regional lymph nodes), vascular involvement, nerve compression, limb dysfunction, increased morbidity and mortality if diagnosis is delayed.
    • Associated Systemic Conditions: Neurofibromatosis (NF1) associated with neurofibromas and MPNST; hereditary leiomyomatosis and renal cell carcinoma (HLRCC); familial adenomatous polyposis (FAP) associated with desmoid tumors.
    • Impact on Regional and Systemic Health: Malignant masses may affect lymphatic drainage, cause regional lymphadenopathy, compromise vascular supply, or lead to systemic effects from metastatic disease.
  • Follow-up Tests
    • For Benign Findings: Clinical examination every 6-12 months; imaging (ultrasound or MRI) only if lesion enlarges or symptoms develop; no routine surveillance needed if diagnosed as lipoma or other clearly benign entity.
    • For Malignant Findings: Metastatic staging with CT chest (primary site for soft tissue sarcoma metastasis), abdominal/pelvic imaging, whole-body PET-CT in select cases; regional lymph node assessment; consideration of genomic testing for targeted therapy.
    • Multidisciplinary Consultation: Orthopedic oncology, surgical oncology, radiation oncology, and medical oncology evaluation for malignant sarcomas to plan multimodal treatment approach.
    • Repeat/Additional Biopsy: If initial results are inconclusive, non-diagnostic, or sample inadequate; core needle biopsy may be upgraded to open or excisional biopsy.
    • Immunohistochemistry and Molecular Studies: Additional testing on biopsy specimen for diagnostic confirmation, prognostic markers, and identification of mutations guiding therapy (e.g., FISH for Ewing sarcoma, MDM2/CDK4 amplification in liposarcoma).
    • Surveillance Protocol for Sarcoma: Clinical assessment every 3 months for first 2 years, then every 6 months for years 3-5; periodic imaging (MRI local site, CT chest); frequency and duration based on grade, stage, and treatment received.
    • Complementary Diagnostic Tests: MRI for precise anatomic assessment and treatment planning; ultrasound for duplex evaluation if vascular involvement suspected; electromyography/nerve conduction studies if neural involvement concerns.
  • Fasting Required?
    • Fasting Required: No fasting is required for thigh mass biopsy.
    • Pre-Procedure Preparation: Patient may eat and drink normally; light meal 2-4 hours before procedure if local anesthesia; NPO (nothing by mouth) 6-8 hours if procedural sedation or general anesthesia planned.
    • Medications to Avoid/Manage: Discontinue antiplatelet agents (aspirin, clopidogrel) 5-7 days prior if possible; hold anticoagulants (warfarin, dabigatran, rivaroxaban) per physician guidelines; continue essential cardiac and blood pressure medications with small sip of water.
    • Laboratory Testing Prior to Biopsy: CBC (complete blood count), PT/INR, aPTT, and type and cross-match or type and screen if general anesthesia planned or significant bleeding risk anticipated.
    • Anesthesia Considerations: Most thigh biopsies performed under local anesthesia with or without conscious sedation; discuss with anesthesia team regarding medication adjustments and NPO status.
    • Imaging Studies: Pre-procedural ultrasound or MRI imaging usually obtained to localize lesion, assess depth and relationship to vital structures, and guide needle placement for optimal sampling.
    • Special Instructions: Inform physician of all medications and supplements; arrange transportation if sedation used; wear loose, comfortable clothing; inform provider of allergies to anesthetics or iodine-based contrast; alert team if history of bleeding disorders or difficult venous access.

How our test process works!

customers
customers